Secnidazole is a 5-nitroimidazole derivative. It penetrates anaerobic microorganisms and protozoa, where it undergoes reduction to form active metabolites that damage microbial DNA. This leads to inhibition of nucleic acid synthesis and ultimately cell death.
It is active against Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia, and various anaerobic bacteria. Its long half-life allows for single-dose or short-course therapy, improving patient compliance.
It may be prescribed by a healthcare provider for:
Secnidazole has been used in clinical practice for decades. Clinical trials have demonstrated high eradication rates in trichomoniasis and bacterial vaginosis with single-dose therapy, showing comparable or superior efficacy to multi-day metronidazole regimens.
Studies confirm a favorable safety profile and good tolerability when used according to recommended guidelines. Secnidazole is included in international treatment protocols for protozoal and anaerobic infections.
The medication works by eliminating protozoa and anaerobic bacteria responsible for inflammatory and infectious conditions of the urogenital tract and gastrointestinal system.
The tablets are taken orally after meals with sufficient water. The dosage regimen and duration of treatment are determined by a healthcare professional depending on the diagnosis and clinical condition. In some cases, single-dose therapy may be prescribed. Alcohol consumption should be avoided during treatment.
Contraindications
Side effects
